- The PharmaJet Tropis Intradermal (ID) Needle-free System will be used exclusively to deliver vaccine to 1.8 million children in upcoming campaign.
- To date, 12+ million pediatric injections have been administered with Tropis in polio vaccination campaigns and routine immunizations across Pakistan, Nigeria, and Somalia.
- Evidence from Tropis use for polio vaccine administration demonstrated improved coverage, acceptability, speed of administration and cost savings.1,2,3,4
GOLDEN, Colo.–(BUSINESS WIRE)–PharmaJet, a company that strives to improve the performance and outcomes of injectables with its innovative needle-free injection technology, today announced that their WHO prequalified Tropis ID Needle-free Injection System will be used in the latest polio immunization campaign in Pakistan, planned for late 2025.
In July 2025, Pakistan announced the expansion of its polio vaccination drive to include children up to age 15.5,6 This is a strategic move in response to a resurgence of wild poliovirus type 1 cases in 2024, when 74 cases were reported,7 and the continued detection of the virus in sewage samples across the country.8,9 The campaign will exclusively use Tropis to deliver fractional dose inactivated polio vaccine (fIPV) to children between 4 months and 15 years of age in Lahore, the largest city in the Pakistani province of Punjab.
Previous campaigns that vaccinated over 12 million children in Pakistan, Nigeria and Somalia showed that Tropis is an effective and preferred solution for polio immunization that can help increase campaign coverage by over 18%.1 The recently published study in Vaccines4 highlighted that, when compared to the standard of care (full dose with needles), Tropis demonstrated increased coverage of the second dose of IPV (IPV2) (11.2% higher); up to 47% total immunization cost savings; and 97% healthcare worker preference. The latest use in Pakistan follows recent news of Tropis adoption for polio vaccination campaigns in Afghanistan.10
“We are pleased that our Tropis ID Needle-free System will continue to be used in polio eradication campaigns in Pakistan,” said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. “Tropis has been shown to be very effective and affordable in campaigns and routine immunizations, protecting over 12 million children against poliovirus. In recognition of World Polio Day 2025, we remain committed to the Global Polio Eradication Initiative, and look forward to continuing to support the fight against poliovirus in this region.”
Refer to Instructions for Use to ensure safe injections and to review risks.
|
1 |
|
Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898 |
|
2 |
|
Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024) |
|
3 |
|
Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291 |
|
4 |
|
Mohan, D et al, Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An implementation hybrid trial, Vaccines, 16 May 2025, 13(5), p.533 |
|
5 |
|
|
|
6 |
|
|
|
7 |
|
WHO Eastern Mediterranean Region’s “Polio Eradication Initiative Report 2024 |
|
8 |
|
National Emergency Operations Centre. (2024, October 17). Sewage samples test positive for poliovirus from 12 districts. End Polio Pakistan. https://www.endpolio.com.pk/media-room/media-releases/2587-sewage-samples-test-positive-for-poliovirus-from-12-districts |
|
9 |
|
World Health Organization, Regional Office for the Eastern Mediterranean. (2024). Polio eradication initiative report 2024: Pakistan. WHO. https://www.emro.who.int/images/stories/pakistan/Polio-report-2024.pdf |
|
10 |
|
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit https://pharmajet.com or contact PharmaJet here. Follow us on LinkedIn.
Contacts
Nancy Lillie
[email protected]
1-888-900-4321 Option 3
